Ignite Creation Date:
2024-05-05 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00478634
Status:
COMPLETED
Last Update Posted:
2012-11-02
First Post:
2007-05-24
Brief Title:
A Phase 1 Study Investigating the Combination of RAD001 Cetuximab and Irinotecan as Second-line Therapy After FOLFOX or XELOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Sponsor:
Organization:
Novartis
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
19
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: